drugset / Trial / NCT05148325
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors
Phase 1
Completed
28 enrolled
Bio-Thera Solutions
Peking University Cancer Hospital & Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
A Phase I Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetics of BAT4706 Injection in Patients With Advanced Solid Tumors.
Timeline
- Start
- 2021-09-02
- Primary completion
- 2024-11-05
- Completion
- 2024-11-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAT4706 | Monoclonal antibody | 0.1 mg/kg | — |
| Subject | BAT4706 | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | BAT4706 | Monoclonal antibody | 0.5 mg/kg | — |
| Subject | BAT4706 | Monoclonal antibody | 1 mg/kg | — |
| Subject | BAT4706 | Monoclonal antibody | 3 mg/kg | — |
| Subject | BAT4706 | Monoclonal antibody | 10 mg/kg | — |